Literature DB >> 20066503

Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients.

Leyla Nazal1, Arnoldo Riquelme, Nancy Solís, Margarita Pizarro, Alex Escalona, Mauricio Burotto, Juan Ignacio Méndez, Catalina Saint-Jean, María José Concha, Stefano Giovanni, Diego Awruch, Arturo Morales, Rene Baudrand, Gonzalo Carrasco, María Angélica Domínguez, Oslando Padilla, Manuel Espinoza, Juan Francisco Miquel, Flavio Nervi, Marco Arrese.   

Abstract

BACKGROUND: Reduced serum levels of adiponectin have been associated with insulin resistance and non-alcoholic fatty liver disease (NAFLD). However, the relationship between serum adiponectin levels and hepatic histology in NAFLD is controversial. The aim of this study was to explore associations between plasma adiponectin concentrations and liver histology in morbidly obese patients.
METHODS: We conducted a case-control study including obese patients undergoing bariatric surgery and normal controls. Anthropometric, standard biochemical variables as well as plasma adiponectin and leptin levels were determined. Liver biopsy was performed in all patients at the time of surgery.
RESULTS: Seventy morbidly obese patients (mean BMI, 40.6 ± 5.6 kg/m(2)) met the inclusion criteria and were compared with 69 controls (mean BMI, 22.8 ± 1.6 kg/m(2), p = 0.0001). Thirty patients (43%) had NAFLD and 20 (28%) of them fulfilled the histological criteria for steatohepatitis. Obesity was associated with increased leptin and decreased adiponectin levels. NAFLD patients exhibited decreased levels of serum adiponectin compared with matched controls [median (Q1-Q3), 3.9 (3.2-4.3) vs. 8.6 (6.5-9.2) μg/mL, p < 0.0001]. In univariate analysis, age, gender, type 2 diabetes mellitus, BMI, HOMA-IR, aspartate aminotransferase (AST), alanine aminotransferase, serum glucose, and adiponectin levels were independently associated with hepatic fibrosis. In multivariate analysis, AST [OR = 1.082 (1.000-1.170)], age [OR = 1.119 (1.023-1.225)], and serum adiponectin levels [OR = 0.529 (0.299-0.936)] were significantly associated with the presence of liver fibrosis.
CONCLUSIONS: NAFLD patients have lower plasma adiponectin concentrations than control subjects. Low adiponectin levels are associated with more severe liver histology. Serum adiponectin may be useful to estimate the severity of liver damage in obese patients with NAFLD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20066503     DOI: 10.1007/s11695-009-0051-0

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  50 in total

1.  Adiponectin--tipping the scales from NAFLD to NASH?

Authors:  Kris V Kowdley; Daniel S Pratt
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

2.  Standards of medical care in diabetes--2007.

Authors: 
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

3.  Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement.

Authors: 
Journal:  Am J Clin Nutr       Date:  1992-02       Impact factor: 7.045

4.  Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study.

Authors:  Raj Vuppalanchi; Smitha Marri; Dhanashri Kolwankar; Robert V Considine; Naga Chalasani
Journal:  J Clin Gastroenterol       Date:  2005-03       Impact factor: 3.062

5.  Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.

Authors:  Camilo Boza; Arnoldo Riquelme; Luis Ibañez; Ignacio Duarte; Enrique Norero; Paola Viviani; Alejandro Soza; Jose Ignacio Fernandez; Alejandro Raddatz; Sergio Guzman; Marco Arrese
Journal:  Obes Surg       Date:  2005-09       Impact factor: 4.129

Review 6.  Roles of adipokines in liver injury and fibrosis.

Authors:  Jianhua Wang; Joanne Brymora; Jacob George
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-02       Impact factor: 3.869

7.  Visceral fat, waist circumference, and BMI: impact of race/ethnicity.

Authors:  Joan F Carroll; Ana L Chiapa; Mayra Rodriquez; David R Phelps; Kathryn M Cardarelli; Jamboor K Vishwanatha; Sejong Bae; Roberto Cardarelli
Journal:  Obesity (Silver Spring)       Date:  2008-01-17       Impact factor: 5.002

Review 8.  Adiponectin: an update.

Authors:  M Guerre-Millo
Journal:  Diabetes Metab       Date:  2008-02       Impact factor: 6.041

9.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

10.  The natural history of nonalcoholic fatty liver: a follow-up study.

Authors:  M R Teli; O F James; A D Burt; M K Bennett; C P Day
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

View more
  6 in total

1.  The relationship of plasma adiponectin with liver fibrosis in morbid obesity.

Authors:  Teoman Dogru; Nuri Karadurmus; Guldem Kilciler; Serkan Tapan; Cemal Nuri Ercin
Journal:  Obes Surg       Date:  2010-10       Impact factor: 4.129

2.  GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells.

Authors:  Xiao-Min Xin; Mu-Xiao Zhong; Gong-Li Yang; Yao Peng; Ya-Li Zhang; Wei Zhu
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 3.  Nonmedicinal interventions in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Radu M Nanau; Lawrence B Cohen
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

Review 4.  Adiponectin as a novel biomarker for liver fibrosis.

Authors:  Wanvisa Udomsinprasert; Sittisak Honsawek; Yong Poovorawan
Journal:  World J Hepatol       Date:  2018-10-27

5.  Historical Changes in Weight Classes and the Influence of NAFLD Prevalence: A Population Analysis of 34,486 Individuals.

Authors:  Benjamin Kai Yi Nah; Cheng Han Ng; Kai En Chan; Caitlyn Tan; Manik Aggarwal; Rebecca Wenling Zeng; Jieling Xiao; Yip Han Chin; Eunice X X Tan; Yi Ping Ren; Douglas Chee; Jonathan Neo; Nicholas W S Chew; Michael Tseng; Mohammad Shadab Siddiqui; Arun J Sanyal; Yock Young Dan; Mark Muthiah
Journal:  Int J Environ Res Public Health       Date:  2022-08-11       Impact factor: 4.614

6.  NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD.

Authors:  Münevver Demir; Sonja Lang; Martin Schlattjan; Uta Drebber; Inga Wedemeyer; Dirk Nierhoff; Ingrid Kaul; Jan Sowa; Ali Canbay; Ulrich Töx; Hans-Michael Steffen
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.